Welcome to our dedicated page for NewGenIvf Group SEC filings (Ticker: NIVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NewGenIvf Group Limited (NIVF) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. NewGenIvf files reports with the U.S. Securities and Exchange Commission primarily on Form 20-F and Form 6-K, detailing its evolving business across fertility services, technology licensing, digital assets, and real estate development.
Investors can review Form 6-K current reports that furnish unaudited interim financial results, describe changes to the company’s capital structure, and attach key press releases. Recent 6-Ks have covered multiple reverse stock splits, increases in authorized share capital, and updates on issued and outstanding shares. These filings explain how reverse splits affect the number of Class A ordinary shares and the adjustment of options, warrants, and convertible securities.
Other 6-K submissions include exhibits for announcements such as the share repurchase program, joint venture and joint development arrangements in Ras Al Khaimah, digital asset and tokenization agreements, and the non-binding term sheet for a proposed reverse merger with SAXA, Inc. Together, these documents outline NewGenIvf’s diversification into technology-driven fertility solutions, digital asset strategies, and UAE real estate projects.
On Stock Titan, each NIVF filing is paired with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand items like capital changes, financing agreements, and strategic transactions. Users can monitor new 6-Ks as they are posted to EDGAR, and refer to annual 20-F reports for a more comprehensive view of NewGenIvf’s business description, risk factors, and financial statements.
NewGenIvf Group Ltd executive Fong Hei Yue Tina, who serves as Chief Marketing Officer and director, has filed a Form 3 reporting beneficial ownership of 39 Class B Ordinary Shares. This filing reflects an initial statement of holdings, with no buy or sell transactions indicated in the data.
NewGenIvf Group Ltd director files initial ownership report. Director Ching Chan Florianna Ann Chi Wan submitted a Form 3 as an insider of NewGenIvf Group Ltd. The filing reports no insider transactions, exercises, gifts, or restructurings and serves only as an initial statement of beneficial ownership.
NewGenIvf Group Ltd director Tam Chun Wa submitted an initial ownership report on Form 3. The filing lists Tam Chun Wa as a director of the company but does not report any share purchases, sales, or other insider transactions.
NewGenIvf Group Ltd director Au Hok Man Jefferson has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. This filing establishes his status as a director at NewGenIvf, and the accompanying data show no insider buy, sell, or derivative transactions reported in this Form 3.
NewGenIvf Group Ltd Chief Financial Officer Chan Chung Ho has filed an initial insider ownership report on Form 3 for the company’s ordinary shares. The filing lists him as an officer with the title Chief Financial Officer and does not report any insider transactions in the available data.
NewGenIvf Group Limited registers the resale of up to 100,000,000 Class A Ordinary Shares to satisfy registration rights held by certain selling securityholders, including shares issuable to White Lion Capital and JAK Opportunities VI LLC pursuant to various note conversions and warrant exercises.
The prospectus states the company is not selling any shares here and will not receive resale proceeds; however, NewGenIvf may receive up to $500,000,000 from sales to White Lion under the White Lion Purchase Agreement, subject to conditions. The prospectus lists selling methods and distributions including brokerage, block trades, and underwritten offerings.
Key context: last reported close was $0.50 (reported March 12, 2026), outstanding shares were 2,273,790 Class A and 275 Class B as of March 12, 2026, and the company regained Nasdaq minimum bid-price compliance after reverse stock splits and received transfer approval to the Nasdaq Capital Market on February 27, 2025.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every four existing shares. This affects Class A and Class B ordinary shares and preferred shares.
The reverse split will be effective at 12:01 a.m. ET on March 16, 2026, and Class A ordinary shares will begin trading on Nasdaq on a split-adjusted basis that day, continuing under the symbol NIVF with a new CUSIP G0544E147. The number of outstanding Class A ordinary shares will change from 2,273,790 to approximately 568,323 shares. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one whole share. Options, warrants and other convertible securities will be adjusted by dividing their underlying share amounts by four.
NewGenIvf Group Limited registers for the resale of up to 100,000,000 Class A Ordinary Shares by selling securityholders, constituting privately issued shares being registered for resale.
The prospectus states the Company is not selling these shares and will not receive proceeds from resale; it may, however, receive up to $500,000,000 under the White Lion Purchase Agreement subject to its terms. Shares outstanding were 2,273,790 Class A Ordinary Shares and 275 Class B Ordinary Shares as of March 2, 2026.
NewGenIvf Group Limited is implementing a reverse stock split of all issued and unissued shares at a ratio of one new share for every three existing shares. This affects Class A ordinary shares, Class B ordinary shares and preferred shares and was approved by the board under BVI law without a shareholder vote.
The reverse split will be effective at 12:01 a.m. (ET) on January 26, 2026, with Class A ordinary shares beginning Nasdaq trading on a split-adjusted basis the same day under the symbol NIVF and a new CUSIP. The number of outstanding Class A ordinary shares will change from 2,948,080 to approximately 982,694, with every three pre-split shares automatically becoming one post-split share. No fractional shares will be issued; holders otherwise entitled to a fraction will receive one full share. Outstanding options, warrants and other convertible securities will be adjusted by dividing the underlying share amounts by three.